EUVIMEDEUVIMED entdecken
Crossref

Hematologic Toxicity Patterns and Prognostic Value of Complete Blood Count in Advanced HR-positive/HER2-negative Breast Cancer Treated with Palbociclib plus Letrozole: A Real-World Single-Center Study

Adnan Mustafa Isamail, Eman Saadi Saleh, Ahmed Zuhair Alsammarraie

Pharmaceutical Sciences · 31.10.2026 · 32 (4) · 632-639

DOI: 10.34172/ps.43631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Sciences, online erschienen am 08.06.2026. Verfasst von Adnan Mustafa Isamail und 2 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The prognostic value of complete blood count (CBC) parameters in patients with advanced HR-positive/HER2-negative breast cancer receiving palbociclib plus letrozole remains unclear. This study aimed to characterize hematologic toxicity patterns associated with treatment response and survival in real-world setting.

Methods

This prospective single-center study included 80 women receiving palbociclib plus letrozole. CBC was collected at baseline and after each of six cycles. Toxicities were graded by CTCAE v5.0. Analyses were descriptive with repeated-measures ANOVA, and ROC curve analysis.

Results

Most hematologic toxicities were grade 1-2; grade 3-4 neutropenia was uncommon and no febrile events occurred. Higher mean WBC and RBC counts during treatment were significantly associated with non-response and shorter progression-free survival (PFS).

Conclusion

Palbociclib plus letrozole showed a manageable safety profile without cumulative hematologic toxicity. Higher on-treatment WBC and RBC counts are prognostic for poorer outcomes. Routine CBC monitoring may offer a low-cost tool to identify patients at risk for treatment failure.

Zitieren

APA

Isamail, A. M., Saleh, E. S., & Alsammarraie, A. Z. (2026). Hematologic Toxicity Patterns and Prognostic Value of Complete Blood Count in Advanced HR-positive/HER2-negative Breast Cancer Treated with Palbociclib plus Letrozole: A Real-World Single-Center Study. Pharmaceutical Sciences, 32(4), 632-639. https://doi.org/10.34172/ps.43631

Vancouver

Isamail AM, Saleh ES, Alsammarraie AZ. Hematologic Toxicity Patterns and Prognostic Value of Complete Blood Count in Advanced HR-positive/HER2-negative Breast Cancer Treated with Palbociclib plus Letrozole: A Real-World Single-Center Study. Pharmaceutical Sciences. 2026;32(4):632-639. doi:10.34172/ps.43631

BibTeX
@article{Isamail2026,
  author = {Isamail, Adnan Mustafa and Saleh, Eman Saadi and Alsammarraie, Ahmed Zuhair},
  title = {Hematologic Toxicity Patterns and Prognostic Value of Complete Blood Count in Advanced HR-positive/HER2-negative Breast Cancer Treated with Palbociclib plus Letrozole: A Real-World Single-Center Study},
  journal = {Pharmaceutical Sciences},
  year = {2026},
  volume = {32},
  number = {4},
  pages = {632--639},
  doi = {10.34172/ps.43631}
}
Kostenlos starten →